Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06031818 | Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Prediction | unknown | — | 80 | Maastricht UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06234553 | Application of Radiomics in the Diagnosis and Treatment Prediction of Pituitary Adenoma(RIPA) | unknown | — | 200 | Beijing Tiantan HospitalOTHER | 1 | Feb 6, 2024 |
| clinicaltrials |
| NCT06244446 | Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma. | unknown | — | 40 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04161287 | Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE | unknown | — | 330 | Beijing 302 HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05526573 | Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions | unknown | — | 148 | Azienda Sanitaria-Universitaria Integrata di UdineOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03799939 | Chimney Trial of Parastomal Hernia Prevention | unknown | N/A | 141 | University of OuluOTHER | 2 | Feb 1, 2024 | clinicaltrials |
| NCT04560894 | SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 405 | Sinocelltech Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05266937 | Atezolizumab Plus CArboplatin Plus Nab-paclitaxel | unknown | Phase 2 | 49 | Consorzio OncotechOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT04682847 | Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers | unknown | — | 40 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06233994 | A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma | unknown | N/A | 30 | Changsha Taihe HospitalOTHER_GOV | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06222944 | Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA | unknown | Phase 2 | 90 | Peking UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT05062837 | Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | unknown | Phase 2 / Phase 3 | 62 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05711823 | Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC | unknown | Phase 3 | 300 | Guangxi Medical UniversityOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05910970 | Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation(PREVENT-2) | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04914390 | A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer(NeoATCT) | unknown | Phase 2 | 32 | Sichuan Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06182644 | Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors(FAPI) | unknown | N/A | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT04224480 | Longitudinal Immune-phenotyping of HCC Following MK-3475 | unknown | Phase 1 | 8 | National Cancer Centre, SingaporeOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT06214533 | Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery(CEBOIDS) | unknown | N/A | 60 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT05293158 | Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study(HBIG) | unknown | N/A | 5 | Medical University of GrazOTHER | 0 | Jan 18, 2024 | clinicaltrials |
| NCT06210438 | SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases | unknown | Phase 2 | 24 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT04800497 | The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC | unknown | — | 70 | University of Milano BicoccaOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04883450 | PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer(PRO-TECT) | unknown | — | 126 | Kaiser PermanenteOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05954442 | Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype(BCTOP-T-M03) | unknown | Phase 3 | 203 | Fudan UniversityOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05962450 | Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy | unknown | Phase 2 | 84 | Beijing YouAn HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06205732 | A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer. | unknown | — | 100 | Qianfoshan HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06207292 | Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer(STARTNEWERA-OM) | unknown | N/A | 100 | Radiotherapy Oncology Centre "Santa Maria" HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05021250 | SBRT With DIBH for HCC After TACE and Lipiodol Marking | unknown | N/A | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT02037048 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | unknown | Phase 2 | 63 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05185531 | A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma(Notable-HCC) | unknown | Phase 1 | 20 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06192030 | Machine Learning Predicts Survival and Mutations in Ovarian Metastases of Colorectal Cancer | unknown | — | 200 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06178809 | Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma | unknown | — | 475 | Singlera Genomics Inc.INDUSTRY | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06144385 | A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | unknown | Phase 1 | 20 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06171854 | caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.(ABACO) | unknown | Phase 2 | 33 | University of Campania Luigi VanvitelliOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT04401059 | Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study(SELECT-2) | unknown | Phase 4 | 744 | Tian XieOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06182735 | CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma | unknown | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06182865 | A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy | unknown | N/A | 10 | National Atomic Research Institute, TaiwanOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04422249 | A Study of Laparoscopic Middle Hepatic Vein Guidance and Traditional Anatomic Hemihepatectomy | unknown | N/A | 95 | Southwest Hospital, ChinaOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT05031949 | Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma(CCGLC-003) | unknown | Phase 1 | 20 | Zhang Bi Xiang, MDOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05103007 | PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer(CCGLC-004) | unknown | N/A | 200 | Tongji HospitalOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05520801 | Primary Hepatobiliary Cancer Cohort of Central China(CCGLC-002) | unknown | — | 2,000 | Tongji HospitalOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05533892 | Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC(CCGLC-007) | unknown | Phase 1 | 30 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05839197 | A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC(CCGLC-010) | unknown | Phase 2 | 38 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT03812393 | Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast(FACT-2) | unknown | Phase 2 | 27 | West Cancer CenterOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04197687 | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | unknown | Phase 2 | 480 | Academic and Community Cancer Research UnitedOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04559607 | TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma | unknown | N/A | 188 | Zhongda HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT05070156 | B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma | unknown | Early Phase 1 | 3 | Tongji UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06172647 | Mucosa Adherent Intestinal Microbiome in Microscopic Colitis and Colorectal Cancer(CMBACT) | unknown | — | 60 | Hospital Mutua de TerrassaOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06168552 | Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer(CISPD-6) | unknown | Phase 1 / Phase 2 | 20 | Zhejiang UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT06163365 | Inherited Cancer Early Diagnosis (ICED) Study(ICED) | unknown | — | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Dec 8, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 6, 2024source: clinicaltrials